Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck(German Center for Lung Research), Tony Mok(Chinese University of Hong Kong), Makoto Nishio(The Cancer Institute Hospital), Robert M. Jotte(Texas Oncology), Federico Cappuzzo(Azienda Unità Sanitaria Locale Della Romagna), Francesco Orlandi(Instituto Nacional del Tórax), Daniil Stroyakovskiy(Shikoku Cancer Center), Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria), Delvys Rodríguez‐Abreu(Hospital Universitario Insular de Gran Canaria), Denis Moro‐Sibilot(Centre Hospitalier Universitaire de Grenoble), Christian A. Thomas(Centre National de la Recherche Scientifique), Fabrice Barlési(Centre National de la Recherche Scientifique), Gene Finley(Allegheny Health Network), Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin(Florida Hospital Cancer Institute), Mark A Socinski(Florida Hospital Cancer Institute), Martin Reck(Chinese University of Hong Kong), Tony Mok(Chinese University of Hong Kong), Makoto Nishio(Texas Oncology), Robert M. Jotte(Azienda Unità Sanitaria Locale Della Romagna), Federico Cappuzzo(Instituto Nacional del Tórax), Francesco Orlandi(Instituto Nacional del Tórax), Daniil Stroyakovskiy(Shikoku Cancer Center), Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria), Delvys Rodríguez‐Abreu(Hospital Universitario Insular de Gran Canaria), Denis Moro‐Sibilot(Centre Hospitalier Universitaire de Grenoble), Christian A. Thomas(Centre National de la Recherche Scientifique), Fabrice Barlési(Centre National de la Recherche Scientifique), Gene Finley(Allegheny Health Network), Anthony Lee, Shelley Coleman, Yu Deng, Marcin Kowanetz, Geetha Shankar, Wei Lin(Florida Hospital Cancer Institute), Mark A Socinski(Florida Hospital Cancer Institute)
Cited by 935
Abstract
Related Papers
No related papers found
Powered by citation graph analysis